Topical pan-LOX Inhibitor (PXS-6302)

Pharmaxis is developing a topical drug inhibiting all lysyl oxidase family members with potential anti-fibrotic application in severe fibrotic related scarring indications. Skin scarring after events such as accidents, surgery or burns place a substantial physical and psychological burden on patients. 

The Pharmaxis discovery, known as PXS-6302, has shown promising pre-clinical results in inhibiting the enzymes that play a critical role in the development of scar tissue. PXS-6302 was discovered by the Pharmaxis research team at the company’s Frenchs Forest laboratories. The project had research funding support for some of the pre-clinical development work done in collaboration with UWA’s Dr Mark Fear from the National Health and Medical Research Council (NHMRC).

The program commenced an independent investigator phase 1 clinical trial in the first quarter of 2021. Read the announcement here. The world-first human trial will determine the safety and tolerability of the product in healthy volunteers, which will lead to further trials in burns and surgical patients.

Distinguished surgeon and burns expert Professor Fiona Wood AM is leading a group of researchers from the University of Western Australia (UWA) and Fiona Stanley Hospital to test the treatment in the first human trials. Professor Fiona Wood said, “It’s exciting for the research team to explore a novel path to reduce scarring and to be moving closer to that goal. Scar-less healing is the vision that has motivated our work over many decades.”

Dr Kylie Sandy-Hodgetts, Senior Research Fellow at the School of Biomedical Sciences, UWA, said, “Current treatments aim to rectify the scar in the acute phase such as during wound healing and scar maturation through options such as compression therapy, silicone gel sheeting or when the scar is established by cryotherapy, scar revision or laser with limited outcomes at times.”

“This new compound may potentially avoid the need for invasive procedures such as further surgery or laser procedures. What we’re hoping is that this new cream may have the potential to improve scar outcomes in patients following surgery,” Dr Sandy-Hodgetts said.

Wound and Burns Scars

Phase I
Description Phase 1a Healthy Volunteers
Sites University of Western Australia and Fiona Stanley Hospital
Subjects 10
Status Complete
More Information
Media Releases